⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

December 3, 2020Journal of Medical EconomicsOpen Access

Healthcare resource utilization and costs for hip dislocation following primary total hip arthroplasty in the medicare population

Jack Mantel A.S. Chitnis Jill Ruppenkamp Chantal E. Holy Juan Daccach

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

This large US retrospective database study demonstrated the substantial HCRU and cost burden of THA dislocation.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Mantel et al. (2020) studied this question.

synapsesocial.com/papers/69dd4b7f99c691022d99bce4 https://doi.org/10.1080/13696998.2020.1854989

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Hospital Cost of Treating Early Dislocation following Hip ArthroplastyOriginal Research · 2012 · 53 citations
2A financial analysis of revision hip arthroplastyOriginal Research · 2012 · 324 citations
3The functional and financial impact of isolated and recurrent dislocation after total hip arthroplastyCohort Study · 2015 · 60 citations
4Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data2005 · 10,717 citations
5Comorbidity Measures for Use with Administrative DataOriginal Research · 1998 · 9,938 citations
6Trends And Geographic Variations In Major Surgery For Degenerative Diseases Of The Hip, Knee, And SpineOriginal Research · 2004 · 195 citations
7Geographical Variation in Outcomes of Primary Hip and Knee ReplacementRegistry Study · 2019 · 37 citations
8Total hip arthroplastyOriginal Research · 2018 · 162 citations
9Cost-effectiveness of onabotulinumtoxinA versus topiramate in chronic migraine in the US: an economic analysis of the FORWARD randomized trialJournal of Medical Economics · 2026
10Overcoming barriers for expanding market access to follow-on biologics in lower-middle-income countriesJournal of Medical Economics · 2026

More from Journal of Medical Economics

More from Johnson & Johnson (United States)